Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · IEX Real-Time Price · USD
6.04
-0.01 (-0.17%)
Jul 22, 2024, 10:19 AM EDT - Market open
Zevra Therapeutics Employees
As of December 31, 2023, Zevra Therapeutics had 69 total employees, including 65 full-time and 4 part-time employees. The number of employees increased by 33 or 91.67% compared to the previous year.
Employees
69
Change (1Y)
33
Growth (1Y)
91.67%
Revenue / Employee
$405,899
Profits / Employee
-$737,739
Market Cap
251.75M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
MultiPlan | 2,800 |
AirSculpt Technologies | 381 |
AVITA Medical | 207 |
Codexis | 174 |
Nektar Therapeutics | 137 |
Senseonics Holdings | 132 |
Profound Medical | 131 |
Nanobiotix | 102 |
ZVRA News
- 27 days ago - Zevra Therapeutics Expands Executive Leadership Team - GlobeNewsWire
- 4 weeks ago - Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders - PRNewsWire
- 6 weeks ago - Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates - GlobeNewsWire
- 2 months ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA - PRNewsWire
- 2 months ago - Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024 - GlobeNewsWire
- 3 months ago - Zevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024 - GlobeNewsWire
- 3 months ago - Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting - GlobeNewsWire